Novartis Bolsters Pipeline with ADC Deal, Pelacarsen Readout on Horizon

What happened

Novartis continues its strategy of in-licensing and bolt-on acquisitions, announcing the purchase of Myricx Bio to bolster its ADC pipeline with novel NMTi payloads, though commercial impact remains years away. The company also highlighted upcoming pivotal data for Avidity's del-brax and Ionis's pelacarsen in the second half of the year, both offering multibillion-dollar peak sales potential. The DeepValue master report maintains a 'POTENTIAL SELL' rating, noting that the stock already prices in strong offset of Entresto LOE and sustained growth from a few oncology/neurology assets. Myricx and the late-stage readouts are part of the broader pipeline-building narrative, but they do not alleviate near-term risks from generic erosion and margin dilution from $12B+ in acquisitions. At ~19.5x trailing EPS, the risk-reward remains unfavorable, with limited multiple expansion potential and visible earnings risks in 2026-2027.

Implication

While the Myricx acquisition and upcoming pelacarsen/del-brax readouts reinforce Novartis's long-term growth narrative, the stock's current price (~$144, 19.5x P/E) leaves little room for error. The commercial impact of Myricx is several years away, and pivotal data, while promising, are binary events. Given the crowded sentiment, visible LOE headwinds from Entresto, and potential margin dilution from acquisitions, the risk-reward skews negative over the next 6-18 months. A better entry point would be below $125, providing a margin of safety for the pipeline story to play out.

Thesis delta

The new ADC deal and specific timing of late-stage readouts add specificity to the pipeline build known from earlier reports, but do not change the fundamental risk/reward calculus. The thesis remains cautious: the market already prices in successful pipeline execution, leaving little valuation upside and meaningful downside if any catalyst falters.